Literature DB >> 3606067

In vitro activity of BMY-28100 against common isolates from pediatric infections.

R K Scribner, M I Marks, B D Finkhouse.   

Abstract

The antibacterial activity of BMY-28100, a new oral cephalosporin, was measured against 300 bacterial isolates from pediatric infections by standard agar dilution methodology. The effect of inoculum size on activity was also assessed. BMY-28100 was more active than cephalexin or cefaclor against all bacterial species tested.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3606067      PMCID： PMC174793          DOI： 10.1128/AAC.31.4.630

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.

Authors:  D A Conrad; R K Scribner; A H Weber; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

2.  Inoculum size effect on the MIC of cefoperazone, moxalactam, cefotaxime, cefoxitin and cephalothin for 118 strains of Haemophilus influenzae including 'tolerant' micro-organisms.

Authors:  P Simard; M G Bergeron
Journal:  J Antimicrob Chemother       Date:  1982-11       Impact factor: 5.790
  2 in total
  14 in total

1.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women.

Authors:  A Iravani
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

3.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Authors:  R H Barbhaiya; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

5.  Five-day versus ten-day treatment of acute otitis media with cefprozil.

Authors:  D A Kafetzis; H Astra; L Mitropoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

6.  Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

7.  Penetration of cefprozil into tonsillar and adenoidal tissues.

Authors:  W C Shyu; J Reilly; D A Campbell; R B Wilber; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 8.  Comparative studies of cefprozil in the management of skin and soft-tissue infections.

Authors:  T Nolen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

Review 9.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

10.  Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis.

Authors:  J C Christenson; E Swenson; W M Gooch; J N Herrod
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.